Trial Profile
A Prospective, Multi-center Phase II Trial on the Efficacy and Safety of Low-dose Erlotinib Monotherapy for Frail Patients with EGFR Mutation-positive, Non-small Cell Lung Cancer(TORG1425)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Final overall survival results presented at the 20th World Conference on Lung Cancer.
- 23 Oct 2018 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Primary endpoint (Independent review committee (IRC)-confirmed objective response rate (ORR) to the low-dose erlotinib) has been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.